Weisrock Fabian, Fritschka Max, Beckmann Sebastian, Litmeier Simon, Wagner Josephine, Tahirovic Elvis, Radenovic Sara, Zelenak Christine, Hashemi Djawid, Busjahn Andreas, Krahn Thomas, Pieske Burkert, Dinh Wilfried, Düngen Hans-Dirk
1 Department of Cardiology, Charité Universitätsmedizin, Campus Virchow-Klinikum, Berlin, Germany.
2 Department of Internal Medicine - Cardiology, Deutsches Herzzentrum Berlin, Germany.
Vasc Med. 2017 Aug;22(4):292-300. doi: 10.1177/1358863X17706752. Epub 2017 May 30.
Endothelial dysfunction plays a major role in cardiovascular diseases and pulse amplitude tonometry (PAT) offers a non-invasive way to assess endothelial dysfunction. However, data about the reliability of PAT in cardiovascular patient populations are scarce. Thus, we evaluated the test-retest reliability of PAT using the natural logarithmic transformed reactive hyperaemia index (LnRHI). Our cohort consisted of 91 patients (mean age: 65±9.7 years, 32% female), who were divided into four groups: those with heart failure with preserved ejection fraction (HFpEF) ( n=25), heart failure with reduced ejection fraction (HFrEF) ( n=22), diabetic nephropathy ( n=21), and arterial hypertension ( n=23). All subjects underwent two separate PAT measurements at a median interval of 7 days (range 4-14 days). LnRHI derived by PAT showed good reliability in subjects with diabetic nephropathy (intra-class correlation (ICC) = 0.863) and satisfactory reliability in patients with both HFpEF (ICC = 0.557) and HFrEF (ICC = 0.576). However, in subjects with arterial hypertension, reliability was poor (ICC = 0.125). We demonstrated that PAT is a reliable technique to assess endothelial dysfunction in adults with diabetic nephropathy, HFpEF or HFrEF. However, in subjects with arterial hypertension, we did not find sufficient reliability, which can possibly be attributed to variations in heart rate and the respective time of the assessments. Clinical Trial Registration Identifier: NCT02299960.
内皮功能障碍在心血管疾病中起主要作用,脉搏振幅张力测量法(PAT)提供了一种评估内皮功能障碍的非侵入性方法。然而,关于PAT在心血管患者群体中可靠性的数据很少。因此,我们使用自然对数转换后的反应性充血指数(LnRHI)评估了PAT的重测可靠性。我们的队列由91名患者组成(平均年龄:65±9.7岁,32%为女性),他们被分为四组:射血分数保留的心力衰竭(HFpEF)患者(n = 25)、射血分数降低的心力衰竭(HFrEF)患者(n = 22)、糖尿病肾病患者(n = 21)和动脉高血压患者(n = 23)。所有受试者在中位间隔7天(范围4 - 14天)内进行了两次单独的PAT测量。PAT得出的LnRHI在糖尿病肾病患者中显示出良好的可靠性(组内相关系数(ICC) = 0.863),在HFpEF患者(ICC = 0.557)和HFrEF患者(ICC = 0.576)中显示出令人满意的可靠性。然而,在动脉高血压患者中,可靠性较差(ICC = 0.125)。我们证明,PAT是评估患有糖尿病肾病、HFpEF或HFrEF的成年人内皮功能障碍的可靠技术。然而,在动脉高血压患者中,我们没有发现足够的可靠性,这可能归因于心率变化和评估的相应时间。临床试验注册标识符:NCT02299960。